Rho GTPase effector functions in tumor cell invasion and metastasis

Current Drug Targets

Volumn 12, Issue 8, 2011, Pages 1194-1201

  Baranwal, Somesh ^a   Alahari, Suresh K ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IQGAP; Oncogenesis; PAK; Rho GTPase; ROCK

Indexed keywords

BETA CATENIN; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; MIXED LINEAGE KINASE 3; P21 ACTIVATED KINASE; PHOSPHOLIPASE C GAMMA1; PHOSPHOLIPASE D1; PROTEIN KINASE C ALPHA; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; STAT3 PROTEIN; SYNAPTOJANIN; UVOMORULIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL POLARITY; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; RAC1 GTP-BINDING PROTEIN; RHO GTP-BINDING PROTEINS;

EID: 79959322098     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795906534     Document Type: Article

References (110)

1. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2(2): 133-42.
2. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. Clin Exp Metastasis 2007; 24(8): 657-72.
3. Grise F, Bidaud A, Moreau V. Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 2009; 1795(2): 137-51.
4. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247-69.
5. Aspenstrom P. Effectors for the Rho GTPases. Curr Opin Cell Biol 1999; 11(1): 95-102.
6. Lemonnier M, Landraud L, Lemichez E. Rho GTPase-activating bacterial toxins: from bacterial virulence regulation to eukaryotic cell biology. FEMS Microbiol Rev 2007; 31(5): 515-34.
7. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009; 1796(2): 91-8.
8. Buongiorno P, Bapat B. Rho GTPases and cancer. Prog Mol Subcell Biol 2005; 40: 29-53.
9. Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010; 115(5): 936-47.
10. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004; 1705(2): 121-32.
11. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007; 29(4): 356-70.
12. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273(5272): 245-8.
13. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996; 271(34): 20246-9.
14. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003; 100(12): 7247-52.
15. Goode BL, Eck MJ. Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem 2007; 76: 593-627.
16. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002; 4(6): 408-15.
17. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 2005; 579(5): 1191-6.
18. Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res 2008; 68(21): 8743-51.
19. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 2006; 26(12): 4612-27.
20. Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003; 9(7): 2632-41.
21. Lane J, Martin TA, Mansel RE, Jiang WG. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int Semin Surg Oncol 2008; 5: 23.
22. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69(22): 8742-51.
23. Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Overexpression of rho effector rhotekin confers increased survival in gastric adenocarcinoma. J Biomed Sci 2004; 11(5): 661-70.
24. Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Rho/Rhotekinmediated NF-kappaB activation confers resistance to apoptosis. Oncogene 2004; 23(54): 8731-42.
25. Eccles SA. Targeting key steps in metastatic tumour progression. Curr Opin Genet Dev 2005; 15(1): 77-86.
26. Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR, Weinstein IB. Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human colon carcinomas and colon carcinoma cell lines. Mol Carcinog 1995; 12(3): 146-52.
27. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 1991; 88(23): 10435-9.
28. Sala G, Dituri F, Raimondi C, et al. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 2008; 68(24): 10187-96.
29. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006; 6(6): 459-71.
30. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 1994; 367(6458): 40-6.
31. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene 2009; 28(28): 2545-55.
32. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol 1997; 7(3): 202-10.
33. Totsukawa G, Wu Y, Sasaki Y, et al. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J Cell Biol 2004; 164(3): 427-39.
34. Davila M, Frost AR, Grizzle WE, Chakrabarti R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 2003; 278(38): 36868-75.
35. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006; 118(11): 2703-10.
36. Brown MC, West KA, Turner CE. Paxillin-dependent paxillin kinase linker and p21-activated kinase localization to focal adhesions involves a multistep activation pathway. Mol Biol Cell 2002; 13(5): 1550-65.
37. Morita T, Mayanagi T, Yoshio T, Sobue K. Changes in the balance between caldesmon regulated by p21-activated kinases and the Arp2/3 complex govern podosome formation. J Biol Chem 2007; 282(11): 8454-63.
38. Lua BL, Low BC. Cortactin phosphorylation as a switch for actin cytoskeletal network and cell dynamics control. FEBS Lett 2005; 579(3): 577-85.
39. Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 2004; 279(7): 6196-203.
40. Grooteclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000; 19(33): 3823-8.
41. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-tomesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res 2005; 65(8): 3179-84.
42. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol 2000; 2(8): 540-7.
43. Humbert PO, Dow LE, Russell SM. The Scribble and Par complexes in polarity and migration: friends or foes? Trends Cell Biol 2006; 16(12): 622-30.
44. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008; 99(9): 1476-83.
45. Nolan ME, Aranda V, Lee S, et al. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 2008; 68(20): 8201-9.
46. Aranda V, Haire T, Nolan ME, et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006; 8(11): 1235-45.
47. Wang HR, Zhang Y, Ozdamar B, et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 2003; 302(5651): 1775-9.
48. Viloria-Petit AM, David L, Jia JY, et al. A role for the TGFbeta- Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci USA 2009; 106(33): 14028-33.
49. White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009; 583(12): 1817-24.
50. Bashour AM, Fullerton AT, Hart MJ, Bloom GS. IQGAP1, a Racand Cdc42-binding protein, directly binds and cross-links microfilaments. J Cell Biol 1997; 137(7): 1555-66.
51. Jadeski L, Mataraza JM, Jeong HW, Li Z, Sacks DB. IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem 2008; 283(2): 1008-17.
52. Nabeshima K, Shimao Y, Inoue T, Koono M. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett 2002; 176(1): 101-9.
53. Zhou R, Skalli O. Identification of cadherin-11 down-regulation as a common response of astrocytoma cells to transforming growth factor-alpha. Differentiation 2000; 66(4-5): 165-72.
54. Patel V, Hood BL, Molinolo AA, et al. Proteomic analysis of lasercaptured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14(4): 1002-14.
55. Roy M, Li Z, Sacks DB. IQGAP1 is a scaffold for mitogenactivated protein kinase signaling. Mol Cell Biol 2005; 25(18): 7940-52.
56. Roy M, Li Z, Sacks DB. IQGAP1 binds ERK2 and modulates its activity. J Biol Chem 2004; 279(17): 17329-37.
57. Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 2008; 20(2): 119-25.
58. Briggs MW, Li Z, Sacks DB. IQGAP1-mediated stimulation of transcriptional co-activation by beta-catenin is modulated by calmodulin. J Biol Chem 2002; 277(9): 7453-65.
59. Wang Y, Wang A, Wang F, et al. IQGAP1 activates Tcf signal independent of Rac1 and Cdc42 in injury and repair of bronchial epithelial cells. Exp Mol Pathol 2008; 85(2): 122-8.
60. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Circ Res 2004; 95(3): 276-83.
61. [Meyer RD, Sacks DB, Rahimi N. IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis. PLoS One 2008; 3(12): e3848.
62. Baranwal S, Alahari SK. Molecular mechanisms controlling Ecadherin expression in breast cancer. Biochem Biophys Res Commun 2009; 384(1): 6-11.
63. Kuroda S, Fukata M, Nakagawa M, et al. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherinmediated cell-cell adhesion. Science 1998; 281(5378): 832-5.
64. Briggs MW, Sacks DB. IQGAP1 as signal integrator: Ca2+, calmodulin, Cdc42 and the cytoskeleton. FEBS Lett 2003; 542(1-3): 7-11.
65. Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ, Sacks DB. IQGAP1 promotes cell motility and invasion. J Biol Chem 2003; 278(42): 41237-45.
66. Hu B, Shi B, Jarzynka MJ, Yiin JJ, D'Souza-Schorey C, Cheng SY. ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer Res 2009; 69(3): 794-801.
67. Brill S, Li S, Lyman CW, et al. The Ras GTPase-activating-proteinrelated human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol 1996; 16(9): 4869-78.
68. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008; 28(5): 1489-502.
69. Nojima H, Adachi M, Matsui T, Okawa K, Tsukita S. IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade. Nat Cell Biol 2008; 10(8): 971-8.
70. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008; 68(8): 2551-6.
71. Pante G, Thompson J, Lamballe F, et al. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol 2005; 171(2): 337-48.
72. Ferby I, Reschke M, Kudlacek O, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006; 12(5): 568-73.
73. Ying H, Zheng H, Scott K, et al. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci USA 2010; 107(15): 6912-7.
74. Reschke M, Ferby I, Stepniak E, et al. Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. Hepatology 2010; 51(4): 1383-90.
75. Jeong JW, Lee HS, Lee KY, et al. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci USA 2009; 106(21): 8677-82.
76. Kim TH, Franco HL, Jung SY, et al. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 2010; 29(26): 3770-80.
77. Manser E, Leung T, Salihuddin H, Tan L, Lim L. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993; 363(6427): 364-7.
78. Lin Q, Lo CG, Cerione RA, Yang W. The Cdc42 target ACK2 interacts with sorting nexin 9 (SH3PX1) to regulate epidermal growth factor receptor degradation. J Biol Chem 2002; 277(12): 10134-8.
79. Howlin J, Rosenkvist J, Andersson T. TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res 2008; 10(2): R36.
80. Malecz N, McCabe PC, Spaargaren C, Qiu R, Chuang Y, Symons M. Synaptojanin 2, a novel Rac1 effector that regulates clathrinmediated endocytosis. Curr Biol 2000; 10(21): 1383-6.
81. Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 2004; 64(22): 8271-5.
82. Bock BC, Vacratsis PO, Qamirani E, Gallo KA. Cdc42-induced activation of the mixed-lineage kinase SPRK in vivo. Requirement of the Cdc42/Rac interactive binding motif and changes in phosphorylation. J Biol Chem 2000; 275(19): 14231-41.
83. Chen J, Miller EM, Gallo KA. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 2010; 29(31): 4399-411.
84. O'Brian C, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49(12): 3215-7.
85. Slater SJ, Seiz JL, Stagliano BA, Stubbs CD. Interaction of protein kinase C isozymes with Rho GTPases. Biochemistry 2001; 40(14): 4437-45.
86. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995; 95(4): 1906-15.
87. Rizzo MA, Shome K, Vasudevan C, et al. Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem 1999; 274(2): 1131-9.
88. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294(5548): 1942-5.
89. Exton JH. Regulation of phospholipase D. FEBS Lett 2002; 531(1): 58-61.
90. Bae CD, Min DS, Fleming IN, Exton JH. Determination of interaction sites on the small G protein RhoA for phospholipase D. J Biol Chem 1998; 273(19): 11596-604.
91. Colley WC, Sung TC, Roll R, et al. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 1997; 7(3): 191-201.
92. Joseph T, Wooden R, Bryant A, Zhong M, Lu Z, Foster DA. Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem Biophys Res Commun 2001; 289(5): 1019-24.
93. Exton JH. Phospholipase D. Biochim Biophys Acta 1998; 1436(1-2): 105-15.
94. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002; 277(5): 3150-7.
95. Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol 2007; 8(1): 37-48.
96. Higgs HN, Pollard TD. Activation by Cdc42 and PIP(2) of Wiskott- Aldrich syndrome protein (WASp) stimulates actin nucleation by Arp2/3 complex. J Cell Biol 2000; 150(6): 1311-20.
97. Rohatgi R, Ho HY, Kirschner MW. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol 2000; 150(6): 1299-310.
98. Chen F, Ma L, Parrini MC, et al. Cdc42 is required for PIP(2)- induced actin polymerization and early development but not for cell viability. Curr Biol 2000; 10(13): 758-65.
99. Kobayashi K, Kuroda S, Fukata M, et al. p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase. J Biol Chem 1998; 273(1): 291-5.
100. Silva JM, Ezhkova E, Silva J, et al. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell 2009; 137(6): 1047-61.
101. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000; 290(5489): 144-7.
102. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4(2): 97-105.
103. Abdulghani J, Gu L, Dagvadorj A, et al. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008; 172(6): 1717-28.
104. Benitah SA, Valeron PF, Rui H, Lacal JC. STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell 2003; 14(1): 40-53.
105. Salomons FA, Acs K, Dantuma NP. Illuminating the ubiquitin/proteasome system. Exp Cell Res 2010; 316(8): 1289-95.
106. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458(7237): 438-44.
107. Jin C, Yang YA, Anver MR, Morris N, Wang X, Zhang YE. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res 2009; 69(3): 735-40.
108. Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008; 135(3): 510-23.
109. Faix J, Grosse R. Staying in shape with formins. Dev Cell 2006; 10(6): 693-706.
110. Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Forminlike 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene 2010; 29(16): 2441-8.